An interventional study of Fecal Microbiota Transplant and Placebo in Anorexia Nervosa Restricting Type, Anorexia Nervosa and Anorexia in Adolescence, sponsored by Hamilton Health Sciences Corporation. Not yet recruiting. Open to female participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Hamilton Health Sciences Corporation · Not applicable, Interventional, and Other
The purpose of this pilot randomized-controlled trial is to determine whether Fecal Microbiota Transplant (FMT) treatment demonstrates feasibility, acceptability, and prelinary effectiveness among patients with anorexia nervosa (AN). Specifically, the investigators aim to compare changes in weight, gut microbiome, urine, blood biomarkers and mood symptoms between participants receiving the FMT intervention and placebo.
In the following pilot randomized-controlled trial, the investigators' aim is to determine whether FMT treatment demonstrates feasibility, acceptability, and preliminary effectiveness in pediatric AN participants. The investigators will assess how the use of FMT affects participants' rate of weight restoration, gut microbiome, relevant urine and blood biomarkers, and mood symptoms. The investigators' rationale for performing the study is to better understand the interactions between the intestinal microbiome, energy regulation, and behavior. This will be the first study to assess the role of FMT in pediatric AN and will help establish whether this adjunctive treatment modality has benefit in managing the metabolic and behavioral manifestations of this complex neuropsychiatric disorder.
In terms of study procedures, members of a pilot sample of 20 AN patients recruited from McMaster Children's Hospital will be randomized to receive FMT or placebo. All participants will be asked to complete a battery of assessments at regular intervals over the 8-week intervention period, and at a follow-up point at four weeks post-intervention.
The study's primary outcomes are recruitment and retention rates. Descriptive statistics will be used to determine the number of adolescents who will agree to participate in the study and those who will complete the study.
One of the study's secondary outcomes is participants' attitudes toward FMT. This will be measured through qualitative interviews among those who completed the intervention and those who do not agree to participate in the study.
The investigators will know we have reached saturation by using a method called "information power" and will explore how broad the research questions are, if there are clear theories to guide the analysis, how varied the participants in the study are, and how much useful information is accrued. Based on this, the investigators will determine the appropriate number of interviews to lead.
The remaining secondary outcome is a battery of preliminary outcomes (clinical, biological, biochemical and safety). The investigators will assess these outcomes at multiple timepoints using questionnaires, anthropometric data, stool analysis (16s rRNA), urine metabolic analysis, saliva ultra filtrates, changes in blood work, and common terminology criteria for adverse events for safety outcomes.
469 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.
This study's planned enrollment of 20 is below the median of 46 across 313 interventional studies indexed under Anorexia Nervosa.
Browse Anorexia Nervosa studies →Hamilton Health Sciences Corporation is the lead sponsor of 242 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: All study subjects will have been diagnosed with AN (restricting type or binge eating/purging type) by the primary physician on the ED team, as per standard approach. Study participants will:
Exclusion Criteria: Potential study subjects will be excluded due to the following reasons:
Banked donor stools that have been previously screened, prepared and frozen per previous protocols will be used to prepare all oral FMT capsules (OFC) through the laboratory of a collaborator. Recipients will receive OFC (two capsules, twice a day, twice per week) prepared from a single donor throughout their 8-week treatment course, to support assessment of FMT engraftment in recipients; this totals to 64 capsules across the duration of the study. Each OFC will contain approximately 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule.
Biological: Fecal Microbiota Transplant
Matching oral placebo capsules (OPC) containing methylcellulose will be identical in terms of size, colour, taste, and dosing. Participants will be asked to take the Placebo treatment capsules twice a day for two days per week for a duration of eight weeks (total 64 capsules).
Drug: Placebo
An investigational biologic comprised of 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule, to be taken twice per day, twice per week over an 8-week duration.
Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
Recruitment Rate
The number of participants who are consented into the study divided by the number of participants who show interest in the study.
Time frame: Through study completion, an average of one year.
Retention Rate
The number of participants who completed the study divided by the number of participants consented into the study.
Time frame: Through study completion, an average of one year.
Attitudes towards Fecal Microbiota Transplant
Attitudes towards FMT will be studied via semi-structured qualitative interviews of all participants: the 20 adolescents and their parents in the trial, and the 10 adolescents and their parents who decline participation, and their guardians. Using Qualitative Description, interviews will explore patient and guardian attitudes toward FMT, as well as their impressions of efficacy (if they participated in the trial). Questions will include perceptions of "natural" versus "drug" products, perspectives on causes of AN, and interests in other potential treatments. Interviews will be conducted virtually, using Zoom for Healthcare, transcribed verbatim and then coded for themes using NVivo. This analysis stays close to the data with little to no interpretation. Our analysis will also include a summative content analysis.
Time frame: Week 12 (follow-up)
Height
Height will be collected.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Weight
Weight will be measured between hospital visits using home weight scales provided to study participants.
Time frame: Week 0 (baseline), Week 2, Week 4 (mid-treatment), Week 6, Week 8 (post-intervention), Week 10, Week 12 (follow-up)
Eating Disorder Examination Questionnaire
The EDEQ is a 28-item standardized questionnaire that measures the severity of symptoms of eating disorders, including menstrual status.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Beck Depression Inventory
The BDI is a 21-item questionnaire used to measure the severity of depressive symptoms.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Beck Anxiety Inventory
The BAI is a 21-item questionnaire used to measure the severity of anxiety symptoms.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Yale-Brown-Cornell Eating Disorder Scale
The YBC-EDS assesses impairment, persistence and degree of obsessional thinking and compulsiveness about eating behaviors.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Gastrointestinal Symptom Rating Scale
This is a 15-item rating scale to capture a variety of GI symptoms.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Changes in stool metabolites
Stool will be collected in to examine changes in alpha- and beta- diversity of microbiota, as well as engraftment of donor specific strains/genes and microbially-derived metabolite levels throughout the study. All stool samples will be collected using an at-home collection kit. Samples will be collected and stored in locked, secure -80°C study freezers upon being brought to the hospital or shipped by paid courier by participants. Stool samples will be sequenced for 16s rRNA gene profiling. All 16s rRNA analyses will be performed using in-house bioinformatics pipelines through the laboratory of a collaborator to identify amplicon sequence variants, perform taxonomic assignments, and analyze alpha- and beta-diversity and differential taxonomic abundance.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Changes in urine metabolomics
Urine samples will be collected from each participant. Nontargeted metabolite profiling is a method used to explore and identify as many metabolites as possible in a sample to identify whatever is present. This approach is designed to help discover new metabolites, and identify changes in metabolite levels that may correlate with other outcomes. We will report differences in highest-abundance metabolites using t-tests to compare their presence between groups, and correlation coefficients to identify associations between outcomes.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Changes in saliva ultrafiltrates
Saliva samples will be collected for metabolomic analysis. Saliva ultrafiltrates will be analyzed as described above for stool and urine samples by a collaborator. All saliva ultrafiltrates will be reported using the same multisegment injection-capillary electrophoresis-mass spectrometer, where metabolites are reported using effect sizes to compare relative concentrations against reference standards.
Time frame: Week 0 (baseline), Week 4 (mid-treatment), Week 8 (post-intervention), Week 12 (follow-up)
Changes in complete blood count
Using the provided blood samples, changes in complete blood count from baseline to post-intervention will be compared using paired t-tests. The complete blood count includes (with their measurement units): Red blood count (RBC)- cells/L Hemoglobin (Hb)- g/L Hematocrit- L/L Mean corpuscular volume (MCV)- fL Mean Corpuscular Hemoglobin (MCH)- pg Mean corpuscular hemoglobin concentration (MCHC)- g/L Red cell distribution width (RDW)- % White blood count (WBC) - cells/L Neutrophils - cells/L Lymphocytes - cells/L Eosinophils - cells/L Basophils - cells/L Monocytes - cells/L
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in C-reactive protein
Using the provided blood samples, changes in C-reactive protein (CRP) from baseline to post-intervention will be compared using paired t-tests. CRP (measured in mg/L) is used to monitor inflammation in acute or chronic conditions.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in alkaline phosphatase
Using the provided blood samples, changes in alkaline phosphatase (ALP) from baseline to post-intervention will be compared using paired t-tests. ALP (measured in U/L) is associated with liver function.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in alanine aminotransferase
Using the provided blood samples, changes in alanine aminotransferase (ALT) from baseline to post-intervention will be compared using paired t-tests. ALT (measured in U/L) is associated with liver function.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in 25-OH Vitamin D
Using the provided blood samples, changes in 25-OH Vitamin D from baseline to post-intervention will be compared using paired t-tests. 25-OH Vitamin D (measured in ng/ml) is used as a measure of Vitamin D levels.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in albumin
Using the provided blood samples, changes in albumin from baseline to post-intervention will be compared using paired t-tests. Albumin (measured in g/L) is associated with liver and kidney function.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in follicle stimulating hormone
Using the provided blood samples, changes in follicle stimulating hormone (FSH) from baseline to post-intervention will be compared using paired t-tests. FSH (measured in mIU/mL) is important for determining aspects of fertility and menstruation.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in luteinizing hormone
Using the provided blood samples, changes in luteinizing hormone (LH) from baseline to post-intervention will be compared using paired t-tests. LH (measured in IU/L) is important for determining aspects of fertility and menstruation.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Changes in free testosterone
Using the provided blood samples, changes in free testosterone from baseline to post-intervention will be compared using paired t-tests. Free testosterone (measured in nmol/L) is important for assessing various bodily functions related to hormones.
Time frame: Week 0 (baseline), Week 8 (post-intervention)
Presence of safety outcomes
Common Terminology Criteria for Adverse Events (CTCAE) will be used to define adverse events and serious adverse events. This framework will be used to classify broad safety concerns throughout our trial.
Time frame: Through study completion, an average of one year.
No study locations are listed for this record.
Plan to share: No — There is no current plan to share individual participant data to other researchers.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 151 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 12 months is below that.
Counting every sponsor, half of 151 studies reached it within 43 months; a quarter within 24 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fecal microbiota
Hamilton Health Sciences Corporation →